Matthew L. Posard
Independent Chairman of the BoardMr. Matthew L. Posard, also known as Matt, has been Director of Vizgen, Inc. since November 2021. He has been Chairman of Nautilus Biotechnology, Inc. since June 9, 2021. He served as an Independent Director of Talis Biomedical Corporation since March 2016 until November 2024. Mr. Posard serves as the Chief Strategist at Deepcell, Inc. He serves as Director at Halozyme, Inc. He served as President and Chief Commercial Officer of GenePeeks, Inc., a genetic research company, from February 2017 to April 2018 and as Executive Vice President and Chief Commercial Officer of Cardiff from March 2015 to May 2016. Mr. Posard served as the Chief Commercial Officer and Executive Vice President at TrovaGene, Inc. (now Cardiff Oncology, Inc.) from March 2015 to April 25, 2016. He is Executive Chairman of Stemson Therapeutics, LLC. He served as executive of Alere, Inc. He served on the Legacy Nautilus Board of Directors from February 2019 to June 9, 2021. Mr. Posard also held multiple executive leadership roles at Illumina, Inc. from February 2006 to February 2015. Mr. Posard served as Senior Vice President and General Manager of Translational & Consumer Genomics at Illumina Inc. He served as Vice President of Marketing of Illumina Inc. since February 2006 and also served as General Manager of new and emerging market opportunities business. He was responsible for all worldwide strategic and tactical marketing for Illumina. Prior to joining Illumina, Mr. Posard held a variety of positions with strategic and the product marketing team at Gen-Probe, Inc., helping it attain leading market positions in DNA probe-based infectious disease diagnostics and blood banking. He has experience identifying, directing and successfully commercializing innovative technologies in the molecular diagnostic and life science fields. Most recently, he spent over many years in various sales and marketing Director positions at Biosite Inc., a San Diego-based developer and provider of diagnostic tests and solutions. While at Biosite, Mr. Posard oversaw the commercialization of several novel products including the successful BNP (B-type natriuretic peptide) heart failure diagnostic test now used in over 50% of U.S. hospitals. Prior to Biosite, he held various marketing positions at Gen-Probe, Inc. managing strategic marketing, new product planning, market research, project management, customer service and sales administration. He serves as a Director of SlipChip Corporation, Omicia and Envision Genomics. He served as Independent Chairman at DermTech, Inc. since August 2019. He had been a Director of DermTech, Inc. since July 11, 2016. He serves as Independent Director at Halozyme Therapeutics, Inc. since March 2013. He serves as a Director of Genomic Healthcare Innovations, Inc. Mr. Posard is a Founding Partner at Explore-DNA, Inc., a life sciences and diagnostics consulting firm, a position he has held since March 2016. Mr. Posard has served on the Board of Directors of Nautilus Biotechnology, Inc. since January 2019. Mr. Posard received a B.A. in Management Science from the University of California, San Diego.
Positions
- Company NameNautilus Biotechnology, Inc.Stock CodeNAUTPositionIndependent Chairman of the BoardColleagues
- SMSujal M. PatelCo-Founder, CEO, President, Secretary & Director
- MLMatthew L. PosardIndependent Chairman of the Board
- PMParag MallickCo-Founder, Chief Scientist & Director
- AMAnna MowryCFO & Treasurer
- MBMatthew B. MurphyGeneral Counsel
- AFAmber FaustVice President of Global Sales
- MMMatthew McIlwainIndependent Director
- MBMelissa B. EpperlyIndependent Director
- Company NameHalozyme Therapeutics, Inc.Stock CodeHALOPositionIndependent DirectorColleagues
- HIHelen I. TorleyPresident, CEO & Director
- JWJeffrey W. HendersonIndependent Chair of the Board
- MSMark SnyderExecutive VP, General Counsel, Chief Compliance Officer & Corporate Secretary
- DSDarren SnellgroveSenior VP & CFO
- BSBrian SweeneyChief Human Resources Officer
- DADavid A. RamsayPresident of Drug Delivery
- GIGregory I. FrostChairman of Scientific Advisory Board
- BMBernadette Mary ConnaughtonIndependent Director
